Base Year
Historical Year
Forecast Year
The dyspepsia market size was valued at USD 1102.4 million in 2023, driven by the rising advancements in medical research and development activities across the 7 major markets. The market is expected to grow at a CAGR of 8.4% during the forecast period of 2024-2032, with the values likely to rise from USD 1192.5 million in 2024 to USD 2268.8 million by 2032.
Dyspepsia, also known as indigestion, is characterized by stomach pain, bloating, and fullness during or after eating. Other symptoms include heartburn, acid reflux, and excessive burping. There are different categories of functional dyspepsia, which involve epigastric pain syndrome as well as postprandial distress syndrome. It may be caused by food allergies, visceral hypersensitivity, and H. pylori infection.
The market growth is driven by the high prevalence of the disease worldwide. The incidence is particularly higher in the western countries, affecting 10% to 40% of the population, while the Asian countries have a prevalence rate of 5% to 30%. Diagnostic tests play a pivot role in offering early treatment, hence, upper endoscopy, breath tests and gastric emptying studies are also used for precise diagnosis.
The increased availability of treatment and drugs in the market are also aiding the dyspepsia market growth. Dyspepsia is treated via medication that works to reduce acid production and block acid pumps. Others may include antibiotics to fight against H. pylori bacteria and prokinetics that tighten the valves between stomach and esophagus, helping in abdominal pain reduction.
Apart from pharmacological interventions, herbal and traditional medicinal approaches are another area of interest amongst researchers. Herbals such as peppermint, caraway oil, and turmeric are heavily investigated and have displayed positive results in patients when compared to regular placebos. This is also indicative of the general market trend of adopting wellness and natural products in combination with pharmaceuticals for disease treatments.
Market Breakup by Diagnosis
Market Breakup by Type
Market Breakup by Indication
Market Breakup by Treatment
Market Breakup by Treatment
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by Region
In the forecast period, the United States is expected to lead the dyspepsia market share. With proactive healthcare and research institutions, there is a heavy emphasis on educating the masses about the condition through early diagnosis and appropriate treatment. In addition, the booming pharmaceutical sector is working on bringing in effective and innovative solutions for patients.
Europe is another major player in the market with a robust healthcare infrastructure, along with rising collaborations between academic and research organizations to develop alternative therapeutics for people. The substantial portion of geriatric population pertaining to the region is another key aspect of the considerable market share of the condition.
The dyspepsia market value is projected to grow with the increasing utility of naturopathy and rising adoption of traditional eastern medicine alternatives for treating the condition. Moreover, the region is witnessing impressive improvements in the medical and research infrastructure which is fostering market growth. Increased influx of foreign capital is another major factor.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
|
Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by Treatment |
|
| Breakup by Treatment Type |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 1102.4 million in 2023, driven by increasing advancements in medical research and development activities across the major markets.
The market is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032, likely to reach a market value of USD 2268.8 million by 2032.
The market demand is majorly driven by the rising prevalence of unhealthy eating habits and increasing incidence of dyspepsia, especially in the Western countries.
The current market trend involves the application of non-pharmacological, herbal, and natural interventions to treat dyspepsia. As per recent studies, peppermint, caraway oil and turmeric have shown promising results in treatment.
The diagnosis can be divided into blood tests, stool tests, breath tests, endoscopy, X-ray, and CT scan, among others.
Based on product type, the market is divided into organic dyspepsia, non-ulcer dyspepsia, and drug induced dyspepsia, among others.
Treatment type includes proton pump inhibitors, H2 blockers, antacids, antibiotics, prokinetics, and antidepressants.
The route of administration can be oral and injectables.
Branded and generic are common drug types available in the market.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Bayer AG, Mankind Pharma, Cadila Pharmaceuticals, Salix Pharmaceuticals, Sanofi, Aosaikand Pharmaceutical Co., Ltd., Hanmi Pharm. Co., Lupin, RedHill Biopharma Ltd., Abbott., GlaxoSmithKline, Johnson&Johnson, Eisai Co Ltd., AstraZeneca, and Allergen Plc.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share